

# Key Partnerships: Community & Private Sector

HIV Cure Initiative  
19 July 2015





# HIV Cure INITIATIVE



Public Private Partnerships Towards a Cure



# WHAT IS THE HIV CURE INITIATIVE

An initiative to **foster public-private partnerships** among international scientific, governmental, philanthropic, industrial, and community **HIV cure stakeholders** that have collectively resolved to identify, test, and distribute interventions that will lead to a drug-free remission (or “cure”) in HIV-infected individuals.

- No single widely accepted definition.
- A government service or private business venture funded/operated through a partnership between a public sector entity and a private sector party.
- Private party will receive a benefit (IP, PR, market position) or fulfill a CSR mission in return for providing a public service or project and assuming financial, technical and/or operational risk.
- Enables the public sector to harness the expertise and efficiencies the private sector can bring to what is otherwise (or traditionally) provided by the public sector.

## Examples

### Qura Therapeutics

- GlaxoSmithKline and University of North Carolina

### Martin Delaney Collaboratories

- Set of research institutions (Hutch, UCSF, UNC) and industry (Merck, Sangamo)

# PPP: PROVEN ECOSYSTEM IN GLOBAL HEALTH


Large  
Pharma &  
Med Tech.




Non-Profit  
PDPs



Smaller Rx  
& Dx



Biotech



**\*\*Does Not Reflect Critical Additional Collaborators:**

**Academic Institutions, Research Institutes, NGOs, Government etc.**

## GOAL: To Facilitate Public-Private Partnerships Focused on HIV Cure

- Global HIV Cure Stakeholders Landscape
- R&D Principles of Engagement
  - Set of commitments & benefits among R&D stakeholder
    - Tech access, data/information sharing, resources
- HIV Cure Investment Case
  - Articulate the economic and public health justification for a cure (1) R&D resource needs, (2) global public health benefits, (3) market analytics
- HIV Cure Roadmap
  - Broad-based, strategic, dynamic and document to identify major barriers to R&D, production and distribution and anticipates milestones (science, funding, policy, IP etc.)

# HIV CURE INITIATIVE EXAMPLE INITIAL PARTICIPANTS

## Argos Therapeutics

International AID  
Society

Institut Pasteur

## Gilead Sciences

FDA

## NIH OAR

White House

Univ. of California San  
Francisco

NIAID

GlaxoSmithKline

Forum for Collaborative  
HIV Research

Genentech

## Merck

Monash University &  
Alfred Hospital

Pfizer

amfAR

## ViiV Healthcare

University of North  
Carolina

Bill & Melinda Gates  
Foundation

IAVI

Sanofi Pasteur

Janssen

Brigham & Women's  
Hospital

Bristol-Myers Squibb

South Africa Medical  
Research Council

University of Southern  
California

Oregon Health & Science  
University

Roche

Elizabeth Glaser Pediatric  
AIDS Found.

National Assoc. of People  
Living With HIV Australia

PATH

IDRI

Profectus Vaccines